Introduction
Bone Morphogenetic Protein 9 (BMP-9), encoded by the GDF2 gene and also designated Growth Differentiation Factor 2 (GDF-2), is a member of the transforming growth factor-beta (TGF-β) superfamily that occupies an unusual dual role in research biology. On one hand, it is widely characterized in the literature as the single most potent osteoinductive BMP family member — outperforming BMP-2, BMP-4, BMP-6, and BMP-7 in driving osteogenic differentiation of mesenchymal stem cells (Kang et al., 2004, PMC529093). On the other hand, it functions physiologically as a circulating vascular quiescence factor, produced primarily by hepatic cells and continuously present in plasma to constrain unwanted endothelial proliferation (David et al., 2008, PMC2561062).
This dual identity — potent morphogen in bone tissue engineering assays, and homeostatic vascular signal in circulation — makes BMP-9 one of the more mechanistically distinct members of the BMP family, and a peptide/protein of substantial interest across skeletal biology, vascular research, and liver biology research programs. This guide provides a complete research profile of BMP-9: its receptor biology, signaling mechanism, primary research domains, and laboratory considerations for researchers investigating this molecule.
This article is intended for laboratory and research purposes only. BMP-9/GDF-2 is a research reagent, not a product for human or animal administration, and none of the information below should be interpreted as guidance for such use.
What Is BMP-9 (GDF-2)?
BMP-9 is a disulfide-linked homodimeric protein synthesized as a large precursor and proteolytically processed to release the mature, biologically active C-terminal growth factor domain — a pattern shared across the TGF-β superfamily. Unlike many BMPs that circulate only locally or transiently, BMP-9 is unusual in that it is detectable as a stable, biologically active mature protein in normal human and rodent plasma, largely uncleaved from its prodomain in circulation, which stabilizes it and modulates its receptor engagement (Nature Communications, 2020).
The primary tissue source of circulating BMP-9 is the liver: hepatic stellate cells, along with liver sinusoidal endothelial cells and Kupffer cells, are established producers of BMP-9 in the adult organism, positioning it as a liver-derived endocrine-like signal rather than a purely local paracrine factor (Bidart et al., 2019, PubMed 30964206; eLife reviewed preprint, 2024).
BMP-9's closest paralog is BMP-10, and the two ligands are frequently studied together because they share the same primary high-affinity receptor complex and substantially overlapping downstream biology, though they are encoded by distinct genes and show some tissue-specific differences in expression and function.
Receptor Biology: ALK1, ALK2, and Endoglin
BMP-9's signaling mechanism is one of the more distinctive stories in the BMP family, because its receptor usage diverges sharply from the "classical" osteogenic BMPs.
Type I receptors. Whereas BMP-2, BMP-4, BMP-6, and BMP-7 signal predominantly through ALK3 (BMPR1A) and ALK6 (BMPR1B), BMP-9 binds with high affinity to ALK1 (ACVRL1) and, more weakly, to ALK2 (ACVR1) (Han et al., 2023, PMC10607732). ALK1 is expressed predominantly on vascular endothelial cells, which is the structural basis for BMP-9's vascular quiescence activity — a receptor distribution pattern quite different from the broadly expressed ALK3/ALK6 receptors used by BMP-2 and BMP-7 (see our BMP-2 and BMP-7 research profiles for direct comparison).
Endoglin (CD105). BMP-9 and BMP-10 are the only known TGF-β superfamily ligands that bind endoglin directly, an auxiliary type III co-receptor expressed at high levels on proliferating and activated endothelium. Endoglin selectively potentiates or restrains BMP-9/ALK1 signaling depending on cellular context, and this specificity is a defining feature of the pathway: endoglin inhibits BMP-9 signaling but does not similarly inhibit BMP-2, BMP-4, or BMP-6 (Blood Cancer Journal, 2014; Journal of Cell Science, 2007).
Downstream signaling. Upon receptor complex assembly, BMP-9/ALK1/endoglin signaling activates the canonical SMAD1/5/8 branch, forming complexes with SMAD4 that translocate to the nucleus and induce transcriptional targets including ID1 and ID3, and upregulate endoglin expression itself in a feed-forward loop (PMC7113306; PMC7867678). In osteogenic contexts, BMP-9 additionally engages p53-dependent signaling that appears to contribute to its superior osteoinductive potency relative to BMP-2 in periosteum-derived cell models (MDPI IJMS, 2023, PMC10607732).
Primary Research Domain 1: Osteogenesis and Bone Tissue Engineering
BMP-9 is consistently identified across the tissue engineering literature as the most potent single BMP for inducing osteoblastic differentiation of mesenchymal stem cells (MSCs) in vitro and bone formation in vivo, outperforming BMP-2 — the field's long-standing reference standard and the only BMP with FDA-approved clinical bone-graft products — across multiple direct comparison studies (Kang et al., PMC3636726; Clinical Implant Dentistry and Related Research, 2026).
Key research findings in this domain include:
- •Dose-response superiority. In periosteum-derived cell models, BMP-9 produces greater osteogenic marker induction than BMP-2 at matched doses, with the differential widening as dose increases, an effect linked mechanistically to p53 pathway engagement unique to BMP-9 (PMC10607732).
- •Gene-delivery approaches. Because recombinant BMP-9 protein is less commercially available and less stable than BMP-2, much of the tissue engineering literature investigates BMP-9 delivered via viral or non-viral gene transfer (including CRISPR-Cas9-mediated overexpression) rather than recombinant protein, and CRISPR-engineered MSCs overexpressing BMP-9 show high in vitro osteogenic potential and enhanced in vivo bone formation in research models (PMC8423866).
- •mRNA-based delivery. Comparative studies using chemically modified mRNA encoding either BMP-2 or BMP-9 have been used as a research platform to evaluate relative bone-regenerative capacity without the stability issues of recombinant protein (PMC5712477).
- •Osseointegration research. More recent implant-focused research (2026) reports BMP-9 outperforming BMP-2 in both osteogenesis and osseointegration metrics in combined in vitro/in vivo models, reinforcing interest in BMP-9 as a next-generation research candidate for dental and orthopedic implant coating strategies (Han et al., Clinical Implant Dentistry, 2026).
Researchers should note that BMP-9's receptor profile (ALK1/ALK2-biased) differs mechanistically from BMP-2's ALK3/ALK6-biased signaling, so equivalent "dose" comparisons across the two ligands reflect differences in both potency and pathway engagement, not a single linear scale.
Primary Research Domain 2: Vascular Quiescence and Endothelial Biology
Independent of its osteogenic activity, BMP-9 functions as a continuously circulating negative regulator of angiogenesis. Physiological concentrations of BMP-9 inhibit basic fibroblast growth factor (bFGF)-induced endothelial cell proliferation and suppress VEGF-stimulated angiogenesis, acting through ALK1 on the vascular endothelium (Journal of Cell Science, 2007). This positions BMP-9 as a "vascular quiescence factor" — a signal that is present at baseline specifically to restrain inappropriate vessel growth rather than to promote it, which is a distinguishing conceptual feature relative to most other angiogenesis-related growth factors studied in vascular biology labs (David et al., PMC2561062).
Recent pulmonary vascular research (2025) using Gdf2 knockout rat models found that loss of BMP-9 leads to augmented pulmonary vascular density and vasodilation, alongside decreased susceptibility to elevated pulmonary vascular resistance in pulmonary hypertension models — findings that implicate BMP-9 in active regulation of pulmonary vascular growth and remodeling, with effects that depend on local receptor abundance, particularly ALK1 (PNAS, 2025).
BMP-9 also induces EphrinB2 expression in endothelial cells through the ALK1-BMPRII/ActRII-ID1/ID3 axis, a pathway of direct relevance to hereditary hemorrhagic telangiectasia type II (HHT2) research models, since EphrinB2 is a marker of arterial endothelial identity implicated in the arteriovenous malformations characteristic of the disease (PubMed 22622516).
Primary Research Domain 3: Hereditary Hemorrhagic Telangiectasia (HHT) Research Models
HHT is a genetic vascular disordercharacterized by arteriovenous malformations, and BMP-9/ALK1/endoglin pathway biology is central to its research models, since loss-of-function mutations in ACVRL1 (encoding ALK1) and ENG (encoding endoglin) are established causes of HHT2 and HHT1, respectively.
Notable research findings include:
- •BMP9/BMP10 emerging roles. A body of literature specifically frames BMP9 and BMP10 as the physiologically relevant ligands for the ALK1/endoglin axis disrupted in HHT, making them central research tools for modeling and probing the disease mechanism rather than incidental bystanders (Ricard et al., PubMed 25620979).
- •BMP9 mutations directly cause vascular anomaly syndromes. Beyond its role as a ligand for HHT-associated receptors, mutations in GDF2 (the BMP-9 gene) itself have been identified as a direct cause of a vascular-anomaly syndrome with substantial phenotypic overlap with HHT, expanding the genetic research landscape for this pathway (Wooderchak-Donahue et al., PubMed 23972370).
- •Antibody-blockade mouse models. Because germline knockouts of BMP9/BMP10 pathway genes can be embryonic lethal or produce confounding developmental phenotypes, researchers have developed a transmammary-delivered immunoblocking approach — administering BMP9/BMP10-neutralizing antibodies to lactating dams to expose pups via milk — as a postnatal, inducible mouse model of HHT-like vascular malformation, a widely cited methodological tool in the field (PMC5118799).
Primary Research Domain 4: Liver Biology and Hepatic Fibrosis
Because the liver is the dominant source of circulating BMP-9, hepatology researchers have investigated its paracrine role within the liver itself, independent of its endocrine effects on distant vascular beds.
BMP-9 has been characterized as a paracrine factor that maintains liver sinusoidal endothelial cell (LSEC) fenestration — the specialized porous architecture of liver capillaries essential for hepatic filtration function — and Bmp9 deletion in mouse models triggers loss of this fenestrated phenotype alongside the development of perisinusoidal fibrosis, indicating a protective role for BMP-9 against hepatic fibrosis in these research models (Desroches-Castan et al., PubMed 30964206). More recent work extends this to a coordinated model in which BMP9 and BMP10 jointly regulate liver cellular crosstalk to maintain overall liver health across endothelial, stellate, and parenchymal cell compartments (eLife reviewed preprint, 2024).
This liver-centric biology is mechanistically important context for any BMP-9 vascular or oncology research design, since it establishes hepatic stellate cells and LSECs as the physiological source tissue that researchers may need to account for when interpreting circulating BMP-9 levels in experimental models.
Primary Research Domain 5: Oncology Research
BMP-9's role in cancer research is context-dependent and, in some models, directly opposed to its pro-osteogenic and pro-fibrotic activity elsewhere. In multiple myeloma research models, BMP-9 has been shown to suppress the growth of myeloma cells by signaling through ALK2, an effect that is inhibited by endoglin — mirroring the same endoglin-restraint mechanism seen in vascular contexts, but here acting as a tumor-growth suppressor rather than a vascular stabilizer (Blood Cancer Journal, 2014; PubMed 24658374).
This context-dependence — vascular quiescence factor, osteogenic morphogen, hepatic protective factor, and tumor-suppressive signal in myeloma, all mediated through overlapping but distinct receptor engagement — is a recurring theme researchers must account for when designing BMP-9 experiments, since the same ligand can produce divergent functional outcomes depending on the receptor repertoire and co-receptor (endoglin) expression of the target cell population.
Laboratory and Research Considerations
Researchers working with BMP-9/GDF-2 in a laboratory setting should note several practical considerations drawn from the literature:
- •Stability and prodomain association. Unlike BMP-2, mature BMP-9 in circulation and in some recombinant preparations remains substantially associated with its prodomain, which affects receptor engagement and should be accounted for when interpreting activity assays or selecting recombinant reagent formats (Nature Communications, 2020).
- •Receptor context matters more than for BMP-2. Because BMP-9 activity depends heavily on local ALK1 and endoglin expression, cell-based assay results can vary substantially between endothelial, osteogenic, and hepatic cell models, and researchers should characterize the receptor expression profile of their chosen cell system before drawing comparative potency conclusions.
- •BMP9/BMP10 cross-reactivity. Given the shared receptor usage between BMP-9 and BMP-10, experimental designs intended to isolate BMP-9-specific effects should consider whether endogenous BMP-10 could confound results, particularly in in vivo or ex vivo tissue models.
- •Delivery format selection. For osteogenic research applications, the literature reflects a substantial shift toward gene- or mRNA-based delivery methods for BMP-9 rather than recombinant protein alone, a consideration for researchers designing bone regeneration or osseointegration studies.
How BMP-9 Compares to Other BMP Family Members
| Feature | BMP-9 (GDF-2) | BMP-2 | BMP-7 |
|---|---|---|---|
| Primary Type I receptor | ALK1 (high affinity), ALK2 (weak) | ALK3, ALK6 | ALK2, ALK3, ALK6 |
| Direct endoglin binding | Yes (with BMP-10) | No | No |
| Circulating in normal plasma | Yes, continuously | Minimal | Minimal |
| Relative osteogenic potency | Highest of BMP family in comparative MSC studies | Reference standard (FDA-approved bone graft use) | Moderate; strong renal/fibrosis research role |
| Signature research domain | Vascular quiescence, HHT, liver fenestration | Bone tissue engineering, spinal fusion research | Kidney development, renal fibrosis research |
See our companion profiles on BMP-2 and SMAD Signaling and BMP-7 for deeper mechanistic comparisons, and our broader TGF-β/SMAD Signaling and Activin A overviews for full TGF-β superfamily context.
Summary
BMP-9/GDF-2 is a mechanistically distinctive member of the TGF-β superfamily, combining the field's most potent single-ligand osteogenic activity with an entirely separate, physiologically dominant role as a liver-derived circulating vascular quiescence factor acting through ALK1 and endoglin. Its research relevance spans bone tissue engineering, pulmonary and systemic vascular biology, hereditary hemorrhagic telangiectasia disease modeling, hepatic fibrosis, and context-dependent oncology research. Researchers selecting BMP-9 for experimental work should account for its prodomain-associated stability profile, its divergence from the ALK3/ALK6-based signaling of classical osteogenic BMPs, and the strong dependence of its functional output on local receptor and endoglin expression.
References
1. Desroches-Castan A, et al. Bone Morphogenetic Protein 9 Is a Paracrine Factor Controlling Liver Sinusoidal Endothelial Cell Fenestration and Protecting Against Hepatic Fibrosis. PubMed. https://pubmed.ncbi.nlm.nih.gov/30964206/
2. Ricard N, et al. Emerging roles of BMP9 and BMP10 in hereditary hemorrhagic telangiectasia. PubMed. https://pubmed.ncbi.nlm.nih.gov/25620979/
3. Wooderchak-Donahue WL, et al. BMP9 mutations cause a vascular-anomaly syndrome with phenotypic overlap with hereditary hemorrhagic telangiectasia. PubMed. https://pubmed.ncbi.nlm.nih.gov/23972370/
4. Kang Q, et al. BMP9 signaling in stem cell differentiation and osteogenesis. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC3636726/
5. David L, et al. Bone morphogenetic protein-9 is a circulating vascular quiescence factor. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC2561062/
6. Scharpfenecker M, et al. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. Journal of Cell Science. https://journals.biologists.com/jcs/article/120/6/964/29968/BMP-9-signals-via-ALK1-and-inhibits-bFGF-induced
7. Alt A, et al. Molecular basis of ALK1-mediated signalling by BMP9/BMP10 and their prodomain-bound forms. Nature Communications. https://www.nature.com/articles/s41467-020-15425-3
8. Ricard N, et al. BMP9 induces EphrinB2 expression in endothelial cells through an Alk1-BMPRII/ActRII-ID1/ID3-dependent pathway: implications for hereditary hemorrhagic telangiectasia type II. PubMed. https://pubmed.ncbi.nlm.nih.gov/22622516/
9. David L, et al. Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin. PubMed. https://pubmed.ncbi.nlm.nih.gov/24658374/
10. Han J, et al. BMP-9 Improves the Osteogenic Differentiation Ability over BMP-2 through p53 Signaling In Vitro in Human Periosteum-Derived Cells. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC10607732/
11. Guo J, et al. Mesenchymal stem cells overexpressing BMP-9 by CRISPR-Cas9 present high in vitro osteogenic potential and enhance in vivo bone formation. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC8423866/
12. Tang Y, et al. Bone morphogenetic protein-9 controls pulmonary vascular growth and remodeling. PNAS. https://www.pnas.org/doi/10.1073/pnas.2410229122
13. BMP9 and BMP10 coordinate liver cellular crosstalk to maintain liver health. eLife. https://elifesciences.org/reviewed-preprints/95811v2
14. Han et al. Bone Morphogenetic Protein (BMP) 9 Outperforms BMP2 in Osteogenesis and Osseointegration: In Vitro and In Vivo. Clinical Implant Dentistry and Related Research. https://onlinelibrary.wiley.com/doi/10.1111/cid.70135
15. Suzuki Y, et al. A mouse model of hereditary hemorrhagic telangiectasia generated by transmammary-delivered immunoblocking of BMP9 and BMP10. PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118799/
This article is for research and educational purposes only. BMP-9/GDF-2 is intended strictly for laboratory research use and is not approved or intended for human or veterinary use, diagnosis, treatment, or prevention of any disease.